Contrasting Cortexyme (NASDAQ:CRTX) & AlloVir (NASDAQ:ALVR)

Risk and Volatility

Cortexyme has a beta of 1.4, indicating that its share price is 40% more volatile than the S&P 500. Comparatively, AlloVir has a beta of 0.63, indicating that its share price is 37% less volatile than the S&P 500.

Institutional and Insider Ownership

63.2% of Cortexyme shares are held by institutional investors. Comparatively, 66.1% of AlloVir shares are held by institutional investors. 27.9% of Cortexyme shares are held by insiders. Comparatively, 32.1% of AlloVir shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Cortexyme and AlloVir”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cortexyme	N/A	N/A	-$89.94 million	($2.97)	-0.66
AlloVir	N/A	N/A	-$190.42 million	($20.23)	-0.40

Cortexyme is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Cortexyme and AlloVir’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cortexyme	N/A	-70.96%	-63.53%
AlloVir	N/A	-71.03%	-61.27%

About Cortexyme

Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

About AlloVir

AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm’s technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.